Business
Conditional Placing of New Ordinary Shares
Conditional Placing of New Ordinary Shares.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \nRNS Number : 5252U Creo Medical Group PLC 13 July 2018 \n\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.\n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \n13 July 2018\n \nCreo Medical Group plc\n \n(\"Creo\" or the \"Company\")\n \nConditional Placing of up to 38,800,000 new Ordinary Shares at 125p per share\n to raise £48.5 million (before expenses) - significantly oversubscribed\n \nand\n \nNotice of General Meeting \n \nCreo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announces that it has conditionally raised, in aggregate, up to £48.5 million (before expenses) by way of three share placings by Cenkos Securities plc (\"Cenkos\") at the Placing Price of 125 pence per Ordinary Share. \n \n \nTransaction Highlights \n \n· Proposed Placing, significantly oversubscribed, to raise up to £48.5 million, in aggregate, before expenses, through the issue of up to 38,800,000 new ordinary shares at the Placing Price of 125 pence per Ordinary Share\n \n· Up to £5 million (before expenses) raised through the EIS/VCT Placing, £3.5 million (before expenses) through the Additional EIS/VCT Placing and £40 million (before expenses) through the Non VCT/EIS Placing\n \n· Expected net proceeds receivable by the Company from the Placing of approximately up to £46 million\n \n· The Placing is conditional, inter alia, upon the Company obtaining approval from its Shareholders to disapply statutory pre-emption rights and to grant the Board authority to allot the Pla...